This Medudy course is a video tutorial for physicians on the topic of "FIRE-4: Anti-EGFR rechallenge with cetuximab in the third line in mCRC with RAS wild type."
The study focuses on the strategic and optimal use of anti-EGFR therapy with cetuximab in metastatic colorectal cancer (mCRC) with RAS wild type across different lines of treatment. Part of the study looked at the best sequencing of anti-EGFR (cetuximab) and anti-VEGF (bevacizumab) strategies in the first line and investigated a possible benefit from early "switch maintenance." The second part of the study, presented at ASCO 2025, focused on the renewed therapeutic efficacy of a cetuximab rechallenge in the third line. The aim is to shed light on the scientific background, study design, and key clinical conclusions of these therapeutic approaches in detail.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Merck.
At the end of this training you will know:
- Strategies for the optimal use of anti-EGFR therapy in mCRC with wild-type RAS.
- The optimal sequencing of anti-EGFR and anti-VEGF strategies in the first line (1L).
- The importance and evidence of the "switch maintenance" approach.
- the efficacy of cetuximab rechallenge in the third line (3L) after an anti-EGFR-free interval.
